Seattle Genetics (SGEN) Stock Value Declined While Benjamin F Edwards & Company Has Increased Its Holding; Fishman Jay A LTD Boosted Stryker (SYK) Position by $14.93 Million; Market Valuation Rose

Seattle Genetics, Inc. (NASDAQ:SGEN) Logo

Fishman Jay A Ltd increased its stake in Stryker Corporation (SYK) by 0.13% based on its latest 2018Q3 regulatory filing with the SEC. Fishman Jay A Ltd bought 84 shares as the company’s stock rose 0.49% while stock markets declined. The institutional investor held 65,170 shares of the medical and dental instruments company at the end of 2018Q3, valued at $11.58 billion, up from 65,086 at the end of the previous reported quarter. Fishman Jay A Ltd who had been investing in Stryker Corporation for a number of months, seems to be bullish on the $68.75 billion market cap company. The stock increased 0.52% or $0.95 during the last trading session, reaching $184.48. About 424,424 shares traded. Stryker Corporation (NYSE:SYK) has risen 13.28% since February 12, 2018 and is uptrending. It has outperformed by 13.28% the S&P500. Some Historical SYK News: 29/03/2018 – Stryker Brings The Mobility Zone™ and Joint Health Education to Houston Open; 07/03/2018 – Stryker’s Spine Division Receives FDA Clearance for 3D-Printed Tritanium TL Curved Posterior Lumbar Cage; 06/03/2018 – Stryker Launches Next Generation Trident® II Acetabular System; 06/03/2018 – Stryker Launches Next Generation Trident® Il Acetabular System; 21/03/2018 – Stryker Hip Lawsuit Attorneys at Bernstein Liebhard LLP Note Upcoming Conferences in New Jersey LFIT V40 Femoral Head Litigation; 23/03/2018 – Stryker F1™ Small Bone Power System brings fresh innovation to the power tool market; 06/04/2018 – Rob Portman: Portman Visits Ohio Troops Abroad, Sees Ohio’s Stryker Dragoon Vehicles & Firsthand Evidence of Russian; 24/04/2018 – FDA: Stryker Instruments Div. of Stryker Corporation- T4 Zipper Toga (S/M); Catalog Number: 0400-810-000 Sterile personal; 19/03/2018 – ClinicalTrial US: Maveric Magnetic Resonance Imaging Used to Study Detailed Bone Apposition and Fixation of the Stryker Trident; 04/04/2018 – AlloSource and Stryker Launch ProChondrix CR Cryopreserved Osteochondral Allograft

Benjamin F Edwards & Company Inc increased its stake in Seattle Genetics Inc (SGEN) by 251.43% based on its latest 2018Q3 regulatory filing with the SEC. Benjamin F Edwards & Company Inc bought 6,160 shares as the company’s stock declined 22.02% with the market. The institutional investor held 8,610 shares of the health care company at the end of 2018Q3, valued at $664,000, up from 2,450 at the end of the previous reported quarter. Benjamin F Edwards & Company Inc who had been investing in Seattle Genetics Inc for a number of months, seems to be bullish on the $10.53B market cap company. The stock decreased 1.43% or $0.95 during the last trading session, reaching $65.58. About 295,078 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 5.90% since February 12, 2018 and is uptrending. It has outperformed by 5.90% the S&P500. Some Historical SGEN News: 09/03/2018 – SEATTLE GENETICS COMPLETES TENDER OFFER FOR ALL SHRS OF CASCADI; 13/04/2018 – Seattle Genetics Presenting at Conference Tomorrow; 26/03/2018 – SEATTLE GENETICS & ASTELLAS GET BREAKTHROUGH DESIGNATION; 26/03/2018 – SEATTLE GENETICS INC – COS ARE ALSO EVALUATING ENFORTUMAB VEDOTIN IN OTHER SOLID TUMORS, INCLUDING OVARIAN AND NON-SMALL CELL LUNG CARCINOMA; 17/05/2018 – Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting; 26/03/2018 – ASTELLAS & SEATTLE GENETICS GET BREAKTHROUGH DESIGNATION FOR EN; 17/05/2018 – Seattle Genetics Presenting at Conference Jun 3; 20/03/2018 – FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with che; 17/05/2018 – SEATTLE GENETICS TO REPORT ENFORTUMAB VEDOTIN STUDY DATA; 20/03/2018 – SEATTLE GENETICS: FDA APPROVES EXPANDED USE FOR ADCETRIS

Fishman Jay A Ltd, which manages about $498.38 million and $569.37 billion US Long portfolio, decreased its stake in Johnson & Johnson (NYSE:JNJ) by 3,150 shares to 152,396 shares, valued at $21.06B in 2018Q3, according to the filing. It also reduced its holding in United Technologies Corp (NYSE:UTX) by 3,000 shares in the quarter, leaving it with 38,602 shares, and cut its stake in Textron Inc (NYSE:TXT).

Since September 4, 2018, it had 2 insider buys, and 11 insider sales for $14.18 million activity. $133,627 worth of Stryker Corporation (NYSE:SYK) was sold by Boehnlein Glenn S on Monday, October 1. Sagar Bijoy also sold $404,289 worth of Stryker Corporation (NYSE:SYK) on Friday, December 7. $14,082 worth of Stryker Corporation (NYSE:SYK) shares were sold by Fink M Kathryn. Owen Katherine Ann sold $6.32M worth of stock. $1.51 million worth of Stryker Corporation (NYSE:SYK) shares were sold by Scannell Timothy J. FRANCESCONI LOUISE also sold $1.68M worth of Stryker Corporation (NYSE:SYK) shares.

More notable recent Stryker Corporation (NYSE:SYK) news were published by: Seekingalpha.com which released: “AMD, BA, VALE among premarket gainers – Seeking Alpha” on January 30, 2019, also Zacks.com with their article: “Here’s Why You Should Invest in Stryker (SYK) Stock Right Now – Zacks.com” published on February 08, 2019, Globenewswire.com published: “Research Report Identifies Stryker, Total System Services, Vista Outdoor, Plains All American Pipeline, Emerson Electric, and IZEA with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement – GlobeNewswire” on January 31, 2019. More interesting news about Stryker Corporation (NYSE:SYK) were released by: Seekingalpha.com and their article: “Stryker Q4 2018 Earnings Preview – Seeking Alpha” published on January 28, 2019 as well as Seekingalpha.com‘s news article titled: “Stryker Corp. (SYK) CEO Kevin Lobo on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: January 29, 2019.

Among 33 analysts covering Stryker Corporation (NYSE:SYK), 23 have Buy rating, 0 Sell and 10 Hold. Therefore 70% are positive. Stryker Corporation had 112 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray with “Buy” on Thursday, October 26. Barclays Capital maintained the shares of SYK in report on Friday, April 28 with “Sell” rating. The firm has “Buy” rating by Cowen & Co given on Wednesday, January 31. The rating was maintained by Stifel Nicolaus with “Buy” on Wednesday, January 31. On Monday, June 19 the stock rating was maintained by Oppenheimer with “Hold”. RBC Capital Markets maintained Stryker Corporation (NYSE:SYK) on Friday, July 28 with “Outperform” rating. BMO Capital Markets maintained Stryker Corporation (NYSE:SYK) rating on Wednesday, April 12. BMO Capital Markets has “Hold” rating and $125 target. The rating was maintained by Jefferies with “Hold” on Tuesday, January 30. The firm has “Outperform” rating given on Wednesday, January 31 by Leerink Swann. As per Monday, July 17, the company rating was maintained by Cowen & Co.

Investors sentiment decreased to 0.97 in Q3 2018. Its down 0.04, from 1.01 in 2018Q2. It is negative, as 32 investors sold SYK shares while 354 reduced holdings. 98 funds opened positions while 278 raised stakes. 265.65 million shares or 1.33% less from 269.24 million shares in 2018Q2 were reported. Idaho-based Caprock Gru has invested 0.07% in Stryker Corporation (NYSE:SYK). 36,809 were reported by Kepos Cap Limited Partnership. Cornerstone holds 0.19% in Stryker Corporation (NYSE:SYK) or 15,000 shares. Lau Assocs Limited Liability Com reported 1,400 shares. Mechanics Commercial Bank Tru Department reported 0.05% stake. Fisher Asset Management Llc holds 0% or 2,733 shares. Moreover, Redmond Asset Mngmt Limited Liability Com has 0.92% invested in Stryker Corporation (NYSE:SYK). 3,992 were accumulated by Van Eck Corp. Etrade Mngmt Limited Liability Corp owns 0.05% invested in Stryker Corporation (NYSE:SYK) for 10,328 shares. Indiana Trust Investment accumulated 4,979 shares or 0.4% of the stock. Great Lakes Advsrs Llc reported 16,054 shares. Amp Cap Invsts Ltd accumulated 133,515 shares. Hills Savings Bank Company accumulated 2,907 shares. Campbell And Co Inv Adviser Ltd Liability Co reported 0.48% stake. 24,504 were reported by Gam Ag.

Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 11 have Buy rating, 0 Sell and 7 Hold. Therefore 61% are positive. Seattle Genetics had 73 analyst reports since July 31, 2015 according to SRatingsIntel. Jefferies maintained Seattle Genetics, Inc. (NASDAQ:SGEN) rating on Tuesday, September 12. Jefferies has “Buy” rating and $53.0 target. On Monday, October 30 the stock rating was maintained by JP Morgan with “Neutral”. As per Tuesday, August 29, the company rating was maintained by Cantor Fitzgerald. H.C. Wainwright maintained Seattle Genetics, Inc. (NASDAQ:SGEN) rating on Friday, October 27. H.C. Wainwright has “Buy” rating and $75.0 target. As per Monday, December 12, the company rating was downgraded by Credit Suisse. The rating was initiated by Morgan Stanley with “Overweight” on Wednesday, September 7. RBC Capital Markets maintained it with “Outperform” rating and $62 target in Monday, October 10 report. H.C. Wainwright maintained it with “Buy” rating and $77.0 target in Wednesday, February 7 report. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Overweight” rating given on Wednesday, February 14 by JP Morgan. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Hold” rating by Cantor Fitzgerald on Wednesday, August 16.

Investors sentiment increased to 1.39 in 2018 Q3. Its up 0.15, from 1.24 in 2018Q2. It increased, as 18 investors sold SGEN shares while 76 reduced holdings. 58 funds opened positions while 73 raised stakes. 158.11 million shares or 1.19% less from 160.01 million shares in 2018Q2 were reported. Ubs Asset Management Americas reported 687,621 shares. Domini Impact Ltd holds 3,057 shares or 3.35% of its portfolio. Swiss National Bank & Trust reported 353,600 shares. Moreover, Natixis has 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN). Proshare Advsr Ltd Liability Co invested in 68,511 shares. Etrade Cap Management Lc accumulated 10,405 shares. Deutsche National Bank & Trust Ag accumulated 70,690 shares or 0% of the stock. Schwab Charles Mgmt holds 0.02% or 406,231 shares. accumulated 9.41 million shares or 0.33% of the stock. First Hawaiian Bank & Trust holds 560 shares. Baillie Gifford Co holds 13.49 million shares. Platinum Invest Mngmt Ltd invested in 0.08% or 34,500 shares. Cibc Asset, a Ontario – Canada-based fund reported 16,897 shares. Lpl Fincl Limited invested in 0.01% or 77,031 shares. Huntington Financial Bank invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN).

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Nasdaq.com which released: “Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release – Nasdaq” on January 31, 2019, also Benzinga.com with their article: “66 Biggest Movers From Friday – Benzinga” published on February 11, 2019, Nasdaq.com published: “SGEN April 18th Options Begin Trading – Nasdaq” on February 12, 2019. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: Seekingalpha.com and their article: “By Besting Herceptin, The Future Is Bright For MacroGenics – Seeking Alpha” published on February 11, 2019 as well as Nasdaq.com‘s news article titled: “After-Hours Earnings Report for February 7, 2019 : FISV, RSG, FTV, VRSN, MSI, DXC, EXPE, MTD, IAC, SGEN, MHK, QRVO – Nasdaq” with publication date: February 07, 2019.

Since August 21, 2018, it had 0 insider purchases, and 16 sales for $13.81 million activity. On Tuesday, January 8 GRYSKA DAVID W sold $325,200 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) or 5,000 shares. SIEGALL CLAY B sold $1.87M worth of stock or 25,000 shares. LIU JEAN I sold $306,058 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, August 27. 5,000 Seattle Genetics, Inc. (NASDAQ:SGEN) shares with value of $310,718 were sold by HIMES VAUGHN B. 5,427 shares were sold by SIMPSON TODD E, worth $402,856.

Benjamin F Edwards & Company Inc, which manages about $3.12 billion and $1.06 billion US Long portfolio, decreased its stake in Teladoc Health Inc by 5,379 shares to 4,460 shares, valued at $385,000 in 2018Q3, according to the filing. It also reduced its holding in First Tr Exchange Traded Fd (FTSM) by 7,461 shares in the quarter, leaving it with 88,558 shares, and cut its stake in Southern Co (NYSE:SO).

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Positions Chart